Oncology and Hematology: Archives

SUMMARY AND COMMENT

Risk-Adapted Management of Early-Stage Testicular Cancer

• May 12, 2009
• Robert Dreicer, MD, MS, FACP

A single course of standard chemotherapy for stage I nonseminomatous germ-cell disease seemed to lower risk for relapse.

• Reviewing:
• Tandstad T et al., J Clin Oncol 2009 May 1; 27:2122 Nichols CR and Kollmannsberger C., J Clin Oncol 2009 May 1; 27:2114

SUMMARY AND COMMENT

Methotrexate or Gefitinib for Head and Neck Cancer?

• May 5, 2009
• Barbara A. Murphy, MD

Overall survival was similar in both treatment arms.

• Reviewing:
• Stewart JSW et al., J Clin Oncol 2009 Apr 10; 27:1864

SUMMARY AND COMMENT

Lymphoma Follow-Up Using PET Imaging

• May 5, 2009
• Michael E. Williams, MD

PET imaging was effective in identifying relapse in patients who were in complete remission.

• Reviewing:
• Zinzani PL et al., J Clin Oncol 2009 Apr 10; 27:1781 Cheson B., J Clin Oncol 2009 Apr 10; 27:1742

SUMMARY AND COMMENT

Hormonal Therapy and Anxiety in Prostate Cancer Patients

• May 5, 2009
• Robert Dreicer, MD, MS, FACP

Anxiety was associated with early initiation of androgen-deprivation therapy.

• Reviewing:
• Dale W et al., J Clin Oncol 2009 Apr 1; 27:1557

SUMMARY AND COMMENT

Markers for Prostate Cancer Lethality

• May 5, 2009
• Robert Dreicer, MD, MS, FACP

Molecular markers of cell-cycle regulation and microvessel density were associated with excess risk for mortality.

• Reviewing:
• Concato J et al., Ann Intern Med 2009 May 5; 150:595 Gelmann EP and Henshall SM., Ann Intern Med 2009 May 5; 150:647

SUMMARY AND COMMENT

Non–Muscle-Invasive Bladder Cancer

• April 28, 2009
• Robert Dreicer, MD, MS, FACP

Treatment intensity did not affect all-cause mortality.

• Reviewing:
• Hollenbeck BK et al., J Natl Cancer Inst 2009 Apr 15; 101:571

SUMMARY AND COMMENT

Gefitinib for Advanced Non–Small-Cell Lung Cancer

• April 28, 2009
• Lin-Chi Chen, MD, PhD

Patients with EGFR mutations and poor performance status benefited from first-line therapy.

• Reviewing:
• Inoue A et al., J Clin Oncol 2009 Mar 20; 27:1394 Langer CJ., J Clin Oncol 2009 Mar 20; 27:1350

SUMMARY AND COMMENT

Azacitidine Dosing for Myelodysplastic Syndromes

• April 28, 2009
• Michael E. Williams, MD

Alternative schedules provided outcomes similar to those achieved with the standard regimen.

• Reviewing:
• Lyons RM et al., J Clin Oncol 2009 Apr 10; 27:1850

SUMMARY AND COMMENT

Oxaliplatin-Induced Neuropathy

• April 21, 2009
• Barbara A. Murphy, MD

Na⁺ channel modulation might be an underlying mechanism.

• Reviewing:
• Park SB et al., J Clin Oncol 2009 Mar 10; 27:1243

SUMMARY AND COMMENT

Trimodality Therapy for Malignant Mesothelioma

• April 21, 2009
• Lin-Chi Chen, MD, PhD

Certain patients who completed trimodality therapy achieved survival benefits.

• Reviewing:
• de Perrot M et al., J Clin Oncol 2009 Mar 20; 27:1413